Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kevin J. Curran"'
Autor:
Maya Eylon, Snehit Prabhu, Samuel John, Maxwell J. M. King, Dhruv Bhatt, Kevin J. Curran, Courtney Erickson, Nicole A. Karras, Christine L. Phillips, Prakash Satwani, Michelle Hermiston, Erica Southworth, Susanne H. C. Baumeister, Julie-An Talano, Margaret L. MacMillan, Jenna Rossoff, Challice L. Bonifant, Gary Doug Myers, Rayne H. Rouce, Keri Toner, Timothy A. Driscoll, Emmanuel Katsanis, Dana B. Salzberg, Deborah Schiff, Satiro N. De Oliveira, Christian M. Capitini, Holly L. Pacenta, Thomas Pfeiffer, Niketa C. Shah, Van Huynh, Jodi L. Skiles, Ellen Fraint, Kevin O. McNerney, Troy C. Quigg, Joerg Krueger, John A. Ligon, Vanessa A. Fabrizio, Christina Baggott, Theodore W. Laetsch, Liora M. Schultz
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionMediport use as a clinical option for the administration of chimeric antigen receptor T cell (CAR T cell) therapy in patients with B-cell malignancies has yet to be standardized. Concern for mediport dislodgement, cell infiltration, and i
Externí odkaz:
https://doaj.org/article/63c1f7316ab94ecab4e03921e246dcfd
Autor:
Alexandre G. Troullioud Lucas, Jaap Jan Boelens, Susan E. Prockop, Kevin J. Curran, Dorine Bresters, Wouter Kollen, Birgitta Versluys, Marc B. Bierings, Anne Archer, Eric Davis, Elizabeth Klein, Nancy A. Kernan, Caroline A. Lindemans, Andromachi Scaradavou
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundPatients with leukemia relapse after allogeneic hematopoietic cell transplant (HCT) have poor survival due to toxicity and disease progression. A second HCT often offers the only curative treatment.MethodsWe retrospectively reviewed our bi-
Externí odkaz:
https://doaj.org/article/4bbe82594c39483eb049ca274f54e3e9